LEXICON PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of -$21.01 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-15.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2019-03-15
- LEXICON PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2017-12-31 was $17.81M.
- LEXICON PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2017-09-30 was $0.00.
- LEXICON PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2017-06-30 was $0.00.
- LEXICON PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2017-03-31 was -$21.01M.
- LEXICON PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2018 was -$21.01M.
- LEXICON PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2017 was -$3.20M.
- LEXICON PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2016 was -$3.20M.
- LEXICON PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2015 was -$750.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month as first filed |
|---|---|---|---|---|---|
| 2018-12-31 | -$21.01M 10-K · filed 2019-03-15 | ||||
| 2017-12-31 | $17.81M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $17.81M derived: sum of 2 quarters · filed 2019-03-15 | $17.81M derived: sum of 3 quarters · filed 2019-03-15 | -$3.20M 10-K · filed 2019-03-15 | -$21.01M 10-K · filed 2018-03-01 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $0.00 derived: sum of 2 quarters · filed 2017-11-08 | -$21.01M 10-Q · filed 2017-11-08 | -$21.01M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | -$21.01M 10-Q · filed 2017-08-01 | -$21.01M derived: sum of 3 quarters · filed 2018-03-01 | ||
| 2017-03-31 | -$21.01M 10-Q · filed 2017-05-04 | -$21.01M derived: sum of 2 quarters · filed 2018-03-01 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$3.20M 10-K · filed 2018-03-01 | |||
| 2016-09-30 | -$3.20M 10-Q · filed 2017-11-08 | ||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $0.00 derived: sum of 2 quarters · filed 2018-03-01 | $0.00 derived: sum of 3 quarters · filed 2018-03-01 | -$750.00K 10-K · filed 2018-03-01 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $0.00 derived: sum of 2 quarters · filed 2016-11-07 | -$750.00K 10-Q · filed 2016-11-07 | ||
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$750.00K 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | -$750.00K 10-Q · filed 2016-05-05 | ||||
| 2014-12-31 | -$11.50M 10-K · filed 2017-03-06 | ||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | -$35.00M 10-K · filed 2015-03-12 | |||
| 2012-09-30 | -$35.00M 10-Q · filed 2013-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |